Clinicoimmunological rationale of interferon therapy in chronic bacterial prostatitis


Cite item

Full Text

Abstract

The study of changes in the immune status of patients with chronic bacterial prostatitis demonstrated changes in immunological parameters reflecting depression of the immune system (subnormal levels of interferon alpha, gamma, sIgA, functional activity of neutrophils, high concentration of IgA, IgG, IgM). Thus, combined treatment of chronic bacterial prostatitis must include administration of immunomodulators.

References

  1. McNaughton Collins M., MacDonald R., Wilt T. J. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann. Intern. Med. 2000; 133 (5): 367-381.
  2. Collins M. M., Barry M. J. Epidemiology of chronic prostatitis. Curr. Opin. Urol. 1998; 8 (1): 33-37.
  3. Diokno A. C. et al. Interstitial cystitis, gynecologic pelvic pain, prostatitis, and their epidemiology. Int. J. Urol. 2003; 10 (suppl.): S3-S6.
  4. Horcajada J. P. et al. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J. Antimicrob. Chemother. 2002; 49 (1): 55-59.
  5. Krieger J. N. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol. Nefrol. 2004; 56 (2): 99-107.
  6. Krieger J. N. et al. Epidemiology of prostatitis: new evidence for a world-wide problem. Wld J. Urol. 2003; 21 (2): 70-74.
  7. Krieger J. N., Ross S. O., Riley D. E. Chronic prostatitis: epidemiology and role of infection. Urology 2002; 60 (6, suppl.): 8- 12; discus.: 13.
  8. Drannik G. N. et al. Local immunity of chronic prostatitis patients. Vestn. Dermatol. 1986; 9: 66-70.
  9. Drannik G. N. et al. T and B. systems of immunity in patients with chronic prostatitis complicated by infertility. Urol. Nefrol. (Mosk.) 1986; 2: 59-61.
  10. Gus'kov A. R., Gorlina N. K., Simonova A. V. Chronic bacterial prostatitis as a manifestation of secondary immunodeficiency state. Zh. Mikrobiol. 1998; 3: 47-51.
  11. Kumon H. Detection of a local prostatic immune response to bacterial prostatitis. Infection 1992; 20 (suppl. 3): S236-S238.
  12. Leport C. et al. Bacterial prostatitis in patients infected with the human immunodeficiency virus. J. Urol. (Baltimore) 1989; 141 (2): 334-336.
  13. Savitskaia K. I. et al. Immuno-microbiological aspects of chronic bacterial prostatitis pathogenesis. Vestn. Ros. Akad. Med. Nauk 1999; 2: 51-58.
  14. Guskov A. R., Gorlina N. K. Immunocorrection therapy in complex treatment of prostatitis. Rus. J. Immunol. 1998; 3 (2): 159- 166.
  15. Rodoman V. E. et al. Immunocorrection in the combined treatment of patients with chronic prostatitis. Vestn. Dermatol. 1983; 9: 69-72.
  16. Seregin S. P. et al. Effect of prostamol-Uno on oxidative and local immune status in patients with benign prostatic hyperplasia and chronic prostatitis. Urologia 2002; 4: 14-16.
  17. Ding X. G. et al. IFN-gamma and TGF-beta1, levels in the expressed prostatic secretions of patients with chronic abacterial prostatitis. Zhonghua Nan Ke Xue 2006; 12 (11): 982-984.
  18. Kalinina S. N., Tiktinskii O. L., Aleksandrov V. P. Clinicoimmunological disorders in patients with chronic prostatitis caused by latent urogenital infection. Urologia 2006; 3: 74-77, 79.
  19. Kodak J. A. et al. Activation of innate immunity by prostate specific antigen (PSA). Prostate 2006; 66 (15): 1592-1599.
  20. Liu H. H. et al. Detection of peripheral blood Th1/Th2 cell ratio in patients with chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue 2006; 12 (4): 330-332, 336.
  21. Motrich R. D. et al. Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin. Immunol. 2005; 116 (2): 149-157.
  22. Chen M., Lin Z., Cao X. Immunological mechanism of human alpha-interferon gene therapy for treatment of melanoma. Zhonghua Zheng Xing Wai Ke Za Zhi 2001; 17 (5): 306-308.
  23. Daines M. O., Hershey G. K. A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha-2 and their rapid mobilization by interferon-gamma. J. Biol. Chem. 2002; 277 (12): 10387-10393.
  24. Kuhen K. L., Samuel C. E. Mechanism of interferon action: functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter. Virology 1999; 254 (1): 182-195.
  25. Tompkins W. A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J. Interferon Cytokine Res. 1999; 19 (8): 817-828.
  26. Benson P. J., Smith C. S. Cytomegalovirus prostatitis. Urology 1992; 40 (2): 165-167.
  27. Coombs R. W. et al. Lower genitourinary tract sources of seminal HIV. J. Acquir. Immune Defic. Syndr. 2006; 41 (4): 430-438.
  28. Dikov D., Chatelet F. P., Dimitrakov J. Pathologic features of necrotizing adenoviral prostatitis in an AIDS patient. Int. J. Surg. Pathol. 2005; 13 (2): 227-231.
  29. Doble A., Harris J. R., Taylor-Robinson D. Prostatodynia and herpes simplex virus infection. Urology 1991; 38 (3): 247-248.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies